The group now has 372 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY 2003-04.
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
The new range of HDPE bottles is compliant with US FDA, EU regulations and Chinese DMF registration for use in dry pharmaceutical applications
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Patent Term Extension is designed to restore some of the patent life lost during the regulatory review process for new drugs.
UTD2 is the world's first oral epothilone microtubule inhibitor
The new API plant is set up to meet all domestic and international regulatory standards and will manufacture niche molecules that have a global requirement
Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 mg and 40 mg had annual sales of USD 42 mn in the United States (IQVIA MAT April 2023)
Construction will begin this year with the new capacity anticipated by 2025
Subscribe To Our Newsletter & Stay Updated
